# Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer

> **NCT00514540** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 121 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Carboplatin
- **DRUG:** Etoposide
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT00514540
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2020-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00514540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00514540, "Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00514540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*